

QUESTION B. WHAT PERCENT OF YOUR PROFESSIONAL TIME IS SPENT IN PATIENT CARE?

	TOTAL
BASE	100
51 - 60 %	4 4.00
61 - 70 %	2 2.00
71 - 80 %	5 5.00
81 - 90 %	22 22.00
91 - 99 %	14 14.00
100 %	53 53.00
MEAN	93.88
STANDARD DEVIATION	9.79
STANDARD ERROR	0.98
MEDIAN	100
SIGMA	100

QUESTION C. WHAT PERCENTAGE OF YOUR PRACTICE IS DEVOTED TO TREATMENT OF BREAST CANCER PATIENTS?

	TOTAL
BASE	100
1 - 10 %	17 17.00
11 - 20 %	35 35.00
21 - 30 %	21 21.00
31 - 40 %	10 10.00
41 - 50 %	4 4.00
51 - 60 %	3 3.00
61 - 70 %	1 1.00
71 - 80 %	3 3.00
81 - 90 %	3 3.00
91 - 99 %	1 1.00
100 %	2 2.00
MEAN	29.38
STANDARD DEVIATION	22.57
STANDARD ERROR	2.26
MEDIAN	20
SIGMA	100

QUESTION D. HOW MANY YEARS HAVE YOU BEEN IN PRACTICE SINCE COMPLETING RESIDENCY OR FELLOWSHIP TRAINING?

	TOTAL
BASE	100
3	2 2.00
4	2 2.00
5	1 1.00
6	3 3.00
7	3 3.00
8	2 2.00
9	4 4.00
10	5 5.00
11	7 7.00
12	5 5.00
13	6 6.00
14	1 1.00
15	2 2.00
16	1 1.00
17	2 2.00
18	2 2.00
19	3 3.00
20	4 4.00
22	2 2.00
23	4 4.00
25	10 10.00
26	1 1.00

QUESTION D. HOW MANY YEARS HAVE YOU BEEN IN PRACTICE SINCE COMPLETING RESIDENCY OR FELLOWSHIP TRAINING?

	TOTAL
BASE	100
27	4 4.00
28	1 1.00
29	2 2.00
30	8 8.00
31	1 1.00
32	4 4.00
34	1 1.00
35	1 1.00
36	1 1.00
38	4 4.00
44	1 1.00
MEAN	19.48
STANDARD DEVIATION	9.93
STANDARD ERROR	0.99
MEDIAN	19
TOTAL	1948
SIGMA	100

(ROTATION A)

QUESTION A1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH INVASIVE BREAST CANCER?

	TOTAL
BASE	20
4	1 5.00
7	1 5.00
15	2 10.00
20	4 20.00
25	1 5.00
30	3 15.00
35	1 5.00
50	2 10.00
85	1 5.00
100	2 10.00
350	1 5.00
400	1 5.00
MEAN (INCLUDING NONE)	70.30
STANDARD DEVIATION (INCLUDING NONE)	108.23
STANDARD ERROR (INCLUDING NONE)	24.20
MEDIAN (INCLUDING NONE)	30
MEAN (EXCLUDING NONE)	70.30
STANDARD DEVIATION (EXCLUDING NONE)	108.23
STANDARD ERROR (EXCLUDING NONE)	24.20
MEDIAN (EXCLUDING NONE)	30
TOTAL	1406
SIGMA	20

(ROTATION A)

QUESTION A2. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH NONINVASIVE BREAST CANCER?

	TOTAL
BASE	20
2	1 5.00
5	3 15.00
6	1 5.00
10	2 10.00
12	1 5.00
20	1 5.00
25	3 15.00
30	2 10.00
75	1 5.00
100	1 5.00
150	4 20.00
MEAN (INCLUDING NONE)	49.25
STANDARD DEVIATION (INCLUDING NONE)	56.96
STANDARD ERROR (INCLUDING NONE)	12.74
MEDIAN (INCLUDING NONE)	25
MEAN (EXCLUDING NONE)	49.25
STANDARD DEVIATION (EXCLUDING NONE)	56.96
STANDARD ERROR (EXCLUDING NONE)	12.74
MEDIAN (EXCLUDING NONE)	25
TOTAL	985
SIGMA	20

(ROTATION A)  
 QUESTION A3. FOR THE FOLLOWING PATIENTS WITH ER+ INVASIVE BREAST CANCERS PRIOR TO THESE ATAC DATA BECOMING AVAILABLE,  
 WHICH STATEMENT BEST DESCRIBES HOW YOU MIGHT MANAGE EACH PATIENT?

\* CLINICAL SCENARIO - ENDOCRINE MANAGEMENT \*  
 INVASIVE ER-POSITIVE

ROTATION A								
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8
AGE	43	43	65	65	65	77	77	77
TUMOR SIZE (CM)	0.8	2.2	0.8	2.2	1.2	0.8	2.2	1.2
NODES	NEG.	NEG.	NEG.	NEG.	1 NODE+	NEG.	NEG.	1 NODE+
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
BASE	20	20	20	20	20	20	20	20
REFER THE PATIENT TO A MEDICAL ONCOLOGIST	12 60.00	17 85.00CF	9 45.00	15 75.00	17 85.00CF	10 50.00	12 60.00	13 65.00
START TAMOXIFEN AND REFER THE PATIENT TO A MEDICAL ONCOLOGIST	5 25.00	3 15.00	4 20.00	4 20.00	3 15.00	2 10.00	4 20.00	6 30.00
MANAGE THE PATIENT PRIMARILY WITH NO ADJUVANT SYSTEMIC THERAPY	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	2 10.00	0 0.00	0 0.00
MANAGE THE PATIENT PRIMARILY WITH TAMOXIFEN	3 15.00	0 0.00	7 35.00BDE H	1 5.00	0 0.00	6 30.00BD EH	4 20.00BE	1 5.00
SIGMA	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)  
 QUESTION A4. NOW PLEASE GO BACK TO THESE SAME CASES, AND ASSUME THAT YOU HAVE HAD A CHANCE TO PERSONALLY ADEQUATELY EVALUATE AND VERIFY THESE ATAC DATA EITHER BY READING A JOURNAL ARTICLE, LISTENING TO AUDIOTAPE, OR ATTENDING A PRESENTATION. WHICH OF THE FOLLOWING STATEMENTS BEST DESCRIBE YOUR CURRENT MANAGEMENT FOR EACH PATIENT BASED ON THE AVAILABILITY OF THESE DATA?

\* CLINICAL SCENARIO - ENDOCRINE MANAGEMENT \*  
 INVASIVE ER-POSITIVE

ROTATION A								
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8
AGE	43	43	65	65	65	77	77	77
TUMOR SIZE (CM)	0.8	2.2	0.8	2.2	1.2	0.8	2.2	1.2
NODES	NEG.	NEG.	NEG.	NEG.	1 NODE+	NEG.	NEG.	1 NODE+
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
BASE	20	20	20	20	20	20	20	20
REFER THE PATIENT TO A MEDICAL ONCOLOGIST	12 60.00	15 75.00	10 50.00	15 75.00	17 85.00CF	10 50.00	12 60.00	16 80.00
START TAMOXIFEN AND REFER THE PATIENT TO A MEDICAL ONCOLOGIST	1 5.00	1 5.00	0 0.00	2 10.00	1 5.00	0 0.00	0 0.00	1 5.00
START ANASTROZOLE AND REFER THE PATIENT TO A MEDICAL ONCOLOGIST	4 20.00	3 15.00	4 20.00	2 10.00	1 5.00	2 10.00	3 15.00	3 15.00
MANAGE THE PATIENT PRIMARILY WITH NO ADJUVANT SYSTEMIC THERAPY	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00
MANAGE THE PATIENT PRIMARILY WITH TAMOXIFEN	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	3 15.00	2 10.00	0 0.00
MANAGE THE PATIENT PRIMARILY WITH ANASTROZOLE	1 5.00	0 0.00	4 20.00BDH	0 0.00	1 5.00	4 20.00BDH	2 10.00	0 0.00
DON'T KNOW	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SIGMA	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION A)  
QUESTION A5. ABOUT HOW MANY OF YOUR CURRENT BREAST CANCER PATIENTS, INVASIVE AND NONINVASIVE, IN YOUR PRACTICE HAVE YOU INITIATED TAMOXIFEN THERAPY ON, WITHOUT A PATIENT SEEING A MEDICAL ONCOLOGIST?

	TOTAL
BASE	20
NONE	8 40.00
1	3 15.00
10	1 5.00
12	1 5.00
15	1 5.00
18	1 5.00
20	2 10.00
27	1 5.00
55	1 5.00
200	1 5.00
MEAN (INCLUDING NONE)	19.00
STANDARD DEVIATION (INCLUDING NONE)	44.80
STANDARD ERROR (INCLUDING NONE)	10.02
MEDIAN (INCLUDING NONE)	1
MEAN (EXCLUDING NONE)	31.67
STANDARD DEVIATION (EXCLUDING NONE)	55.03
STANDARD ERROR (EXCLUDING NONE)	15.89
MEDIAN (EXCLUDING NONE)	17
TOTAL	380
SIGMA	20

(ROTATION A)  
QUESTION A6. ABOUT HOW MANY OF YOUR CURRENT BREAST CANCER PATIENTS, INVASIVE AND NONINVASIVE, IN YOUR PRACTICE HAVE YOU INITIATED TAMOXIFEN THERAPY ON, AND THEN SENT THE PATIENT TO A MEDICAL ONCOLOGIST?

	TOTAL
BASE	20
NONE	11 55.00
7	1 5.00
10	1 5.00
20	1 5.00
25	1 5.00
30	1 5.00
35	1 5.00
40	1 5.00
50	1 5.00
55	1 5.00
MEAN (INCLUDING NONE)	13.60
STANDARD DEVIATION (INCLUDING NONE)	18.81
STANDARD ERROR (INCLUDING NONE)	4.21
MEAN (EXCLUDING NONE)	30.22
STANDARD DEVIATION (EXCLUDING NONE)	16.60
STANDARD ERROR (EXCLUDING NONE)	5.53
MEDIAN (EXCLUDING NONE)	30
TOTAL	272
SIGMA	20

(ROTATION A)  
QUESTION A7. IF THE ATAC DATA ARE WIDELY ACCEPTED, AND ANASTROZOLE GENERALLY REPLACES TAMOXIFEN AS ADJUVANT ENDOCRINE THERAPY  
FOR POST-MENOPAUSAL WOMEN, WHICH OF THE FOLLOWING BEST DESCRIBES HOW LIKELY IT IS THAT SURGEONS WILL PRESCRIBE ANASTROZOLE?

	TOTAL
BASE	20
VERY LIKELY (4)	6 30.00
LIKELY (3)	5 25.00
SOMEWHAT LIKELY (2)	5 25.00
VERY UNLIKELY (1)	3 15.00
DON'T KNOW	1 5.00
REFUSED	0 0.00
MEAN	2.74
STANDARD DEVIATION	1.10
STANDARD ERROR	0.25
MEDIAN	3.00
SIGMA	20

(ROTATION B)  
QUESTION B1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH INVASIVE BREAST CANCER?

	TOTAL
BASE	20
6	1 5.00
8	1 5.00
10	1 5.00
12	2 10.00
15	1 5.00
20	4 20.00
25	2 10.00
35	1 5.00
40	1 5.00
50	3 15.00
70	1 5.00
120	1 5.00
150	1 5.00
MEAN (INCLUDING NONE)	37.90
STANDARD DEVIATION (INCLUDING NONE)	37.67
STANDARD ERROR (INCLUDING NONE)	8.42
MEDIAN (INCLUDING NONE)	23
MEAN (EXCLUDING NONE)	37.90
STANDARD DEVIATION (EXCLUDING NONE)	37.67
STANDARD ERROR (EXCLUDING NONE)	8.42
MEDIAN (EXCLUDING NONE)	23
TOTAL	758
SIGMA	20

(ROTATION B)

QUESTION B2. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH NONINVASIVE BREAST CANCER?

	TOTAL
BASE	20
4	1 5.00
6	2 10.00
8	1 5.00
10	2 10.00
12	2 10.00
15	1 5.00
20	2 10.00
24	1 5.00
30	2 10.00
40	1 5.00
50	2 10.00
60	2 10.00
300	1 5.00
MEAN (INCLUDING NONE)	38.35
STANDARD DEVIATION (INCLUDING NONE)	64.25
STANDARD ERROR (INCLUDING NONE)	14.37
MEDIAN (INCLUDING NONE)	20
MEAN (EXCLUDING NONE)	38.35
STANDARD DEVIATION (EXCLUDING NONE)	64.25
STANDARD ERROR (EXCLUDING NONE)	14.37
MEDIAN (EXCLUDING NONE)	20
TOTAL	767
SIGMA	20

(ROTATION B)  
 QUESTION B3. THE FOLLOWING PATIENTS PRESENT WITH A SUSPICIOUS BREAST MASS, WHICH ON CORE BIOPSY PROVES TO BE ER+ INVASIVE BREAST CANCER. PRIOR TO THESE ATAC DATA BECOMING AVAILABLE, WHICH STATEMENT BEST DESCRIBES HOW YOU MIGHT MANAGE EACH PATIENT?

\* CLINICAL SCENARIO ENDOCRINE MANAGEMENT \*  
 INVASIVE ER-POSITIVE

ROTATION B												
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
BASE	20	20	20	20	20	20	20	20	20	20	20	20
REFER THE PATIENT TO A MEDICAL ONCOLOGIST FOR CONSIDERATION OF PRE-OP CHEMOTHERAPY THERAPY	2 10.00	6 30.00GK	11 55.00AEGH	10 50.00AEGK	3 15.00	9 45.00AEGK	0 0.00	4 20.00GK	8 40.00AGK	5 25.00GK	0 0.00	5 25.00GK
REFER THE PATIENT TO A MEDICAL ONCOLOGIST FOR CONSIDERATION OF PRE-OP ENDOCRINE THERAPY	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	3 15.00
REFER THE PATIENT TO A MEDICAL ONCOLOGIST FOR CONSIDERATION OF BOTH PRE-OP CHEMOTHERAPY AND ENDOCRINE THERAPY	0 0.00	2 10.00	3 15.00	6 30.00AEGHK	0 0.00	7 35.00AEGHK	1 5.00	1 5.00	3 15.00	10 50.00ABCEGHIK	0 0.00	8 40.00ABEGHJK
MANAGE THE PATIENT WITH SURGERY INITIALLY	18 90.00BCD DFIJJL	11 55.00DF JL	6 30.00JL	2 10.00	17 85.00BC DFIJJL	2 10.00	19 95.00BC DFHIJJL	14 70.00CD FIJL	6 30.00JL	1 5.00	19 95.00BCD FHIJJL	1 5.00
CONSULT WITH ONCOLOGIST BEFORE DECIDING TREATMENT	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00
DON'T KNOW	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	1 5.00	1 5.00	2 10.00	1 5.00	2 10.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)  
 QUESTION B4. NOW PLEASE GO BACK TO THESE SAME CASES, AND ASSUME THAT YOU HAVE HAD A CHANCE TO PERSONALLY ADEQUATELY EVALUATE AND VERIFY THESE ATAC DATA EITHER BY READING A JOURNAL ARTICLE, LISTENING TO AN AUDIOTAPE, OR ATTENDING A PRESENTATION. WHICH OF THE FOLLOWING STATEMENTS BEST DESCRIBES YOUR LIKELY CURRENT MANAGEMENT FOR EACH PATIENT, ASSUMING THE AVAILABILITY OF THESE DATA?

\* CLINICAL SCENARIO ENDOCRINE MANAGEMENT \*  
 INVASIVE ER-POSITIVE

ROTATION B												
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
BASE	20	20	20	20	20	20	20	20	20	20	20	20
REFER THE PATIENT TO A MEDICAL ONCOLOGIST FOR CONSIDERATION OF PRE-OP CHEMOTHERAPY THERAPY	1 5.00	5 25.00GK	9 45.00AB GHK	7 35.00AG K	2 10.00	7 35.00AGK	0 0.00	3 15.00	5 25.00GK	4 20.00GK	0 0.00	4 20.00GK
REFER THE PATIENT TO A MEDICAL ONCOLOGIST FOR CONSIDERATION OF PRE-OP ENDOCRINE THERAPY	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	2 10.00	0 0.00	1 5.00	2 10.00	2 10.00	0 0.00	3 15.00
REFER THE PATIENT TO A MEDICAL ONCOLOGIST FOR CONSIDERATION OF BOTH PRE-OP CHEMOTHERAPY AND ENDOCRINE THERAPY	1 5.00	2 10.00	4 20.00GK	8 40.00AB EGK	2 10.00	7 35.00AGK	0 0.00	3 15.00	5 25.00GK	10 50.00ABE GHK	0 0.00	9 45.00ABEGHK
MANAGE THE PATIENT WITH SURGERY INITIALLY	16 80.00BC DFIJL	9 45.00DF JL	4 20.00	2 10.00	14 70.00CDF IJL	1 5.00	19 95.00BC DEFHIJL	11 55.00CD FJL	6 30.00FJL	1 5.00	18 90.00BCD FHIJL	1 5.00
INITIATE NEOADJUVANT ANASTROZOLE	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
REFER THE PATIENT TO A MEDICAL ONCOLOGIST WITHOUT PRE-OP TREATMENT	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00
DON'T KNOW	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	1 5.00	1 5.00	2 10.00	1 5.00	2 10.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION C)  
 QUESTION C1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH INVASIVE BREAST CANCER?

	TOTAL
BASE	20
NONE	1 5.00
5	1 5.00
10	1 5.00
15	2 10.00
20	2 10.00
25	3 15.00
30	3 15.00
40	2 10.00
50	1 5.00
110	1 5.00
125	1 5.00
150	1 5.00
500	1 5.00
MEAN (INCLUDING NONE)	63.25
STANDARD DEVIATION (INCLUDING NONE)	110.47
STANDARD ERROR (INCLUDING NONE)	24.70
MEDIAN (INCLUDING NONE)	28
MEAN (EXCLUDING NONE)	66.58
STANDARD DEVIATION (EXCLUDING NONE)	112.46
STANDARD ERROR (EXCLUDING NONE)	25.80
MEDIAN (EXCLUDING NONE)	30
TOTAL	1265
SIGMA	20



(ROTATION C)

QUESTION C2. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH NONINVASIVE BREAST CANCER?

	TOTAL
BASE	20
3	1 5.00
5	2 10.00
7	2 10.00
10	1 5.00
17	1 5.00
20	6 30.00
25	1 5.00
30	1 5.00
40	1 5.00
50	2 10.00
75	1 5.00
100	1 5.00
MEAN (INCLUDING NONE)	27.20
STANDARD DEVIATION (INCLUDING NONE)	25.03
STANDARD ERROR (INCLUDING NONE)	5.60
MEDIAN (INCLUDING NONE)	20
MEAN (EXCLUDING NONE)	27.20
STANDARD DEVIATION (EXCLUDING NONE)	25.03
STANDARD ERROR (EXCLUDING NONE)	5.60
MEDIAN (EXCLUDING NONE)	20
TOTAL	544
SIGMA	20

(ROTATION C)  
 QUESTION C3. ABOUT HOW MANY GAIL RISK MODEL ASSESSMENTS, IF ANY, HAVE YOU DONE OR HAS YOUR OFFICE STAFF DONE FOR YOUR PATIENTS IN THE LAST YEAR?

	TOTAL
BASE	20
NONE	9 45.00
2	1 5.00
4	1 5.00
15	1 5.00
25	1 5.00
40	1 5.00
50	1 5.00
70	2 10.00
75	1 5.00
120	1 5.00
200	1 5.00
MEAN (INCLUDING NONE)	33.55
STANDARD DEVIATION (INCLUDING NONE)	52.46
STANDARD ERROR (INCLUDING NONE)	11.73
MEDIAN (INCLUDING NONE)	3
MEAN (EXCLUDING NONE)	61.00
STANDARD DEVIATION (EXCLUDING NONE)	58.19
STANDARD ERROR (EXCLUDING NONE)	17.55
MEDIAN (EXCLUDING NONE)	50
TOTAL	671
SIGMA	20

(ROTATION C)  
 QUESTION C4. ABOUT HOW MANY TOTAL WOMEN HAVE YOU EVALUATED IN YOUR PRACTICE IN THE LAST YEAR THAT WERE HIGH ENOUGH RISK TO CONSIDER SOME TYPE OF INTERVENTION, NOT INCLUDING WOMEN WITH A PERSONAL HISTORY OF BREAST CANCER?

	TOTAL
BASE	20
NONE	2
	10.00
2	1
	5.00
5	1
	5.00
6	3
	15.00
7	1
	5.00
8	1
	5.00
10	2
	10.00
20	1
	5.00
25	2
	10.00
30	1
	5.00
35	1
	5.00
65	1
	5.00
80	1
	5.00
100	1
	5.00
150	1
	5.00
MEAN (INCLUDING NONE)	29.50
STANDARD DEVIATION (INCLUDING NONE)	39.70
STANDARD ERROR (INCLUDING NONE)	8.88
MEDIAN (INCLUDING NONE)	10
MEAN (EXCLUDING NONE)	32.78
STANDARD DEVIATION (EXCLUDING NONE)	40.59
STANDARD ERROR (EXCLUDING NONE)	9.57
MEDIAN (EXCLUDING NONE)	15

(ROTATION C)  
QUESTION C4. ABOUT HOW MANY TOTAL WOMEN HAVE YOU EVALUATED IN YOUR PRACTICE IN THE LAST YEAR THAT WERE HIGH ENOUGH  
RISK TO CONSIDER SOME TYPE OF INTERVENTION, NOT INCLUDING WOMEN WITH A PERSONAL HISTORY OF BREAST CANCER?

	TOTAL
BASE	20
TOTAL	590
SIGMA	20

(ROTATION C AND IF "AT LEAST ONE WOMEN AT ENOUGH RISK TO CONSIDER INTERVENTION" IN QUESTION C4)  
QUESTION C4A. HOW MANY WERE AT RISK DUE TO GENETIC ABNORMALITY?

\* GENETIC ABNORMALITY \*

	TOTAL
BASE	18
NONE	10 55.56
1	2 11.11
2	1 5.56
3	1 5.56
10	2 11.11
30	1 5.56
100	1 5.56
MEAN (INCLUDING NONE)	8.72
STANDARD DEVIATION (INCLUDING NONE)	23.94
STANDARD ERROR (INCLUDING NONE)	5.64
MEAN (EXCLUDING NONE)	19.63
STANDARD DEVIATION (EXCLUDING NONE)	33.88
STANDARD ERROR (EXCLUDING NONE)	11.98
MEDIAN (EXCLUDING NONE)	7
TOTAL	157
SIGMA	18

(ROTATION C AND IF "AT LEAST ONE WOMEN AT ENOUGH RISK TO CONSIDER INTERVENTION" IN QUESTION C4)  
 QUESTION C4A. HOW MANY WERE AT RISK DUE TO GENETIC ABNORMALITY?

\* STRONG FAMILY HISTORY \*

	TOTAL
BASE	18
1	2 11.11
2	3 16.67
5	2 11.11
6	1 5.56
10	1 5.56
15	2 11.11
17	1 5.56
25	1 5.56
33	1 5.56
55	1 5.56
70	1 5.56
74	1 5.56
100	1 5.56
MEAN (INCLUDING NONE)	24.33
STANDARD DEVIATION (INCLUDING NONE)	30.09
STANDARD ERROR (INCLUDING NONE)	7.09
MEDIAN (INCLUDING NONE)	13
MEAN (EXCLUDING NONE)	24.33
STANDARD DEVIATION (EXCLUDING NONE)	30.09
STANDARD ERROR (EXCLUDING NONE)	7.09
MEDIAN (EXCLUDING NONE)	13
TOTAL	438
SIGMA	18

(ROTATION C AND IF "AT LEAST ONE WOMEN AT ENOUGH RISK TO CONSIDER INTERVENTION" IN QUESTION C4)  
 QUESTION C4A. HOW MANY WERE AT RISK DUE TO GENETIC ABNORMALITY?

\* BREAST BIOPSY SHOWING ATYPICAL HYPERPLASIA OR OTHER SIGNIFICANT MARKER \*

	TOTAL
BASE	18
NONE	1
	5.56
1	1
	5.56
2	1
	5.56
3	2
	11.11
4	3
	16.67
5	4
	22.22
6	1
	5.56
10	1
	5.56
15	1
	5.56
20	1
	5.56
25	1
	5.56
50	1
	5.56
MEAN (INCLUDING NONE)	9.28
STANDARD DEVIATION (INCLUDING NONE)	12.15
STANDARD ERROR (INCLUDING NONE)	2.86
MEDIAN (INCLUDING NONE)	5
MEAN (EXCLUDING NONE)	9.82
STANDARD DEVIATION (EXCLUDING NONE)	12.29
STANDARD ERROR (EXCLUDING NONE)	2.98
MEDIAN (EXCLUDING NONE)	5
TOTAL	167
SIGMA	18

(ROTATION C)  
QUESTION C4A. IS THERE AN OTHER MENTIONED?

	TOTAL
BASE	18
YES	2 11.11
NO	16 88.89
SIGMA	18



(ROTATION C AND IF "AN OTHER MENTIONED" IN QUESTION C4A)

QUESTION C4A. WHAT IS THE FIRST OTHER MENTIONED?

	TOTAL
BASE	2
ER+	1
	50.00
AGE AT FIRST PREGNANCY	1
	50.00
SIGMA	2

(ROTATION C AND "ER+" MENTIONED IN QUESTION C4A)

QUESTION C4A. HOW MANY WERE AT RISK DUE TO ER+?

	TOTAL
BASE	1
40	1 100.00
MEAN (INCLUDING NONE)	40.00
MEDIAN (INCLUDING NONE)	40
MEAN (EXCLUDING NONE)	40.00
MEDIAN (EXCLUDING NONE)	40
TOTAL	40
SIGMA	1

(ROTATION C AND "AGE AT FIRST PREGNANCY" MENTIONED IN QUESTION C4A)  
QUESTION C4A. HOW MANY WERE AT RISK DUE TO AGE AT FIRST PREGNANCY?

	TOTAL
BASE	1
3	1
	100.00
MEAN (INCLUDING NONE)	3.00
MEDIAN (INCLUDING NONE)	3
MEAN (EXCLUDING NONE)	3.00
MEDIAN (EXCLUDING NONE)	3
TOTAL	3
SIGMA	1

(ROTATION C AND IF "AT LEAST ONE WOMEN AT ENOUGH RISK TO CONSIDER INTERVENTION" IN QUESTION C4)  
QUESTION C4A. RISK FACTORS

\* SUMMARY OF MEANS (INCLUDING NONE) \*

	TOTAL
BASE	18
GENETIC ABNORMALITY	8.72
STRONG FAMILY HISTORY	24.33
BREAST BIOPSY SHOWING ATYPICAL HYPERPLASIA OR OTHER SIGNIFICANT MARKER	9.28
ER+	40.00
AGE AT FIRST PREGNANCY	3.00

(ROTATION C AND IF "AT LEAST ONE WOMEN AT ENOUGH RISK TO CONSIDER INTERVENTION" IN QUESTION C4)  
QUESTION C4A. RISK FACTORS

\* SUMMARY OF MEANS (EXCLUDING NONE) \*

	TOTAL
BASE	18
GENETIC ABNORMALITY	19.63
STRONG FAMILY HISTORY	24.33
BREAST BIOPSY SHOWING ATYPICAL HYPERPLASIA OR OTHER SIGNIFICANT MARKER	9.82
ER+	40.00
AGE AT FIRST PREGNANCY	3.00

(ROTATION C)  
QUESTION C5. IN THE PAST YEAR, ABOUT HOW MANY HIGH-RISK WOMEN WITH NO PERSONAL HISTORY OF BREAST CANCER HAVE YOU TREATED WITH TAMOXIFEN?

	TOTAL
BASE	20
NONE	15 75.00
2	1 5.00
5	1 5.00
6	1 5.00
8	1 5.00
12	1 5.00
MEAN (INCLUDING NONE)	1.65
STANDARD DEVIATION (INCLUDING NONE)	3.39
STANDARD ERROR (INCLUDING NONE)	0.76
MEAN (EXCLUDING NONE)	6.60
STANDARD DEVIATION (EXCLUDING NONE)	3.71
STANDARD ERROR (EXCLUDING NONE)	1.66
MEDIAN (EXCLUDING NONE)	6
TOTAL	33
SIGMA	20

(ROTATION C)  
QUESTION C6. WHICH OF THE FOLLOWING DESCRIBE WHAT YOU BELIEVE THE RESULTS WOULD BE OF A RANDOMIZED CLINICAL TRIAL COMPARING  
TAMOXIFEN TO ANASTROZOLE IN HIGH RISK POST MENOPAUSAL WOMEN, IN TERMS OF TOXICITY?

	TOTAL
BASE	20
LESS TOXICITY WITH ANASTROZOLE	15 75.00
LESS TOXICITY WITH TAMOXIFEN	1 5.00
NO SIGNIFICANT DIFFERENCE	3 15.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)

QUESTION C6A. AND, IN TERMS OF EFFICACY?

	TOTAL
BASE	20
GREATER BENEFITS WITH ANASTROZOLE	13 65.00
NO SIGNIFICANT DIFFERENCE	5 25.00
DON'T KNOW	2 10.00
SIGMA	20



(ROTATION C)  
QUESTION C7. WHICH OF THE FOLLOWING WOULD APPLY FOR YOU TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN POST MENOPAUSAL HIGH RISK WOMEN?

\* WOULD USE IT NOW BASED ON ATAC DATA \*

	TOTAL
BASE	20
YES	12 60.00
NO	7 35.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)  
QUESTION C7. WHICH OF THE FOLLOWING WOULD APPLY FOR YOU TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN POST MENOPAUSAL HIGH RISK WOMEN?

\* WOULD USE IT IF ATAC TRIAL CONTINUED TO SHOW SIMILAR RESULTS WITH LONGER FOLLOW-UP \*

	TOTAL
BASE	20
YES	16 80.00
NO	4 20.00
SIGMA	20

(ROTATION C)  
QUESTION C7. WHICH OF THE FOLLOWING WOULD APPLY FOR YOU TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN POST MENOPAUSAL HIGH RISK WOMEN?

\* WOULD USE IT IF A PRIMARY PREVENTION TRIAL DEMONSTRATED SAFETY AND EFFICACY IN HIGH-RISK WOMEN \*

	TOTAL
BASE	20
YES	18 90.00
NO	1 5.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)  
QUESTION C7. WHICH OF THE FOLLOWING WOULD APPLY FOR YOU TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN POST MENOPAUSAL  
HIGH RISK WOMEN?

\* WOULD NOT USE IT \*

	TOTAL
BASE	20
YES	1 5.00
NO	19 95.00
SIGMA	20

(ROTATION C)

QUESTION C7. IS THERE SOMETHING ELSE I HAVE NOT DESCRIBED?

	TOTAL
BASE	20
YES	2 10.00
NO	18 90.00
SIGMA	20

(ROTATION C AND IF "SOMETHING ELSE" MENTIONED IN QUESTION C7)  
QUESTION C7. OTHERS MENTIONED

	TOTAL
BASE	2
WOULD USE IT IF ONCOLOGISTS USING ANASTROZOLE IN THAT SETTING INSTEAD OF TAMOXIFEN	1 50.00
WOULD USE IF PATIENT IS ABLE TO MEET COST	1 50.00
SIGMA	2

(ROTATION C)  
QUESTION C7. WHICH OF THE FOLLOWING WOULD APPLY FOR YOU TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN POST MENOPAUSAL HIGH RISK WOMEN?

	TOTAL
BASE	20
WOULD USE IT NOW BASED ON ATAC DATA	12 60.00
WOULD USE IT IF ATAC TRIAL CONTINUED TO SHOW SIMILAR RESULTS WITH LONGER FOLLOW-UP	16 80.00
WOULD USE IT IF A PRIMARY PREVENTION TRIAL DEMONSTRATED SAFETY AND EFFICACY IN HIGH-RISK WOMEN	18 90.00
WOULD NOT USE IT	1 5.00
WOULD USE IT IF ONCOLOGISTS USING ANASTROZOLE IN THAT SETTING INSTEAD OF TAMOXIFEN	1 5.00
WOULD USE IF PATIENT IS ABLE TO MEET COST	1 5.00

(ROTATION C)  
 QUESTION C8. AND HOW MANY WOMEN WITH DCIS DID YOU TREAT IN THE LAST YEAR?

	TOTAL
BASE	20
2	1 5.00
4	2 10.00
5	2 10.00
6	1 5.00
7	2 10.00
10	1 5.00
12	1 5.00
15	1 5.00
20	2 10.00
30	3 15.00
35	1 5.00
40	1 5.00
60	1 5.00
75	1 5.00
MEAN (INCLUDING NONE)	20.85
STANDARD DEVIATION (INCLUDING NONE)	19.93
STANDARD ERROR (INCLUDING NONE)	4.46
MEDIAN (INCLUDING NONE)	14
MEAN (EXCLUDING NONE)	20.85
STANDARD DEVIATION (EXCLUDING NONE)	19.93
STANDARD ERROR (EXCLUDING NONE)	4.46
MEDIAN (EXCLUDING NONE)	14
TOTAL	417
SIGMA	20



(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)  
QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU TREAT WITH MASTECTOMY?

\* TREAT WITH MASTECTOMY \*

	TOTAL
BASE	20
NONE	4
	20.00
1	2
	10.00
2	3
	15.00
3	3
	15.00
4	1
	5.00
5	4
	20.00
6	1
	5.00
10	1
	5.00
30	1
	5.00
MEAN (INCLUDING NONE)	4.35
STANDARD DEVIATION (INCLUDING NONE)	6.55
STANDARD ERROR (INCLUDING NONE)	1.46
MEDIAN (INCLUDING NONE)	3
MEAN (EXCLUDING NONE)	5.44
STANDARD DEVIATION (EXCLUDING NONE)	6.93
STANDARD ERROR (EXCLUDING NONE)	1.73
MEDIAN (EXCLUDING NONE)	4
TOTAL	87
SIGMA	20

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)  
 QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU TREAT WITH LUMPECTOMY AND RADIATION THERAPY?

\* TREAT WITH LUMPECTOMY AND RADIATION THERAPY \*

	TOTAL
BASE	20
NONE	4
	20.00
1	1
	5.00
2	1
	5.00
3	1
	5.00
5	1
	5.00
7	1
	5.00
8	1
	5.00
10	1
	5.00
15	2
	10.00
18	1
	5.00
20	2
	10.00
22	1
	5.00
25	2
	10.00
55	1
	5.00
MEAN (INCLUDING NONE)	12.55
STANDARD DEVIATION (INCLUDING NONE)	13.45
STANDARD ERROR (INCLUDING NONE)	3.01
MEDIAN (INCLUDING NONE)	9
MEAN (EXCLUDING NONE)	15.69
STANDARD DEVIATION (EXCLUDING NONE)	13.29
STANDARD ERROR (EXCLUDING NONE)	3.32
MEDIAN (EXCLUDING NONE)	15
TOTAL	251

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)

QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU TREAT WITH LUMPECTOMY AND RADIATION THERAPY?

\* TREAT WITH LUMPECTOMY AND RADIATION THERAPY \*

	TOTAL
BASE	20
SIGMA	20

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)

QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU TREAT WITH LUMPECTOMY AND NO RADIATION THERAPY?

\* TREAT WITH LUMPECTOMY AND NO RADIATION THERAPY \*

	TOTAL
BASE	20
NONE	10
	50.00
1	3
	15.00
2	3
	15.00
4	1
	5.00
5	1
	5.00
8	1
	5.00
30	1
	5.00
MEAN (INCLUDING NONE)	2.80
STANDARD DEVIATION (INCLUDING NONE)	6.74
STANDARD ERROR (INCLUDING NONE)	1.51
MEDIAN (INCLUDING NONE)	1
MEAN (EXCLUDING NONE)	5.60
STANDARD DEVIATION (EXCLUDING NONE)	8.86
STANDARD ERROR (EXCLUDING NONE)	2.80
MEDIAN (EXCLUDING NONE)	2
TOTAL	56
SIGMA	20

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)  
QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU REFER TO A MEDICAL ONCOLOGIST?

\* REFER TO A MEDICAL ONCOLOGIST \*

	TOTAL
BASE	20
NONE	3 15.00
2	1 5.00
3	1 5.00
4	2 10.00
5	1 5.00
7	1 5.00
10	1 5.00
12	1 5.00
15	1 5.00
20	1 5.00
30	3 15.00
35	1 5.00
40	1 5.00
50	1 5.00
60	1 5.00
MEAN (INCLUDING NONE)	17.85
STANDARD DEVIATION (INCLUDING NONE)	18.12
STANDARD ERROR (INCLUDING NONE)	4.05
MEDIAN (INCLUDING NONE)	11
MEAN (EXCLUDING NONE)	21.00
STANDARD DEVIATION (EXCLUDING NONE)	17.88
STANDARD ERROR (EXCLUDING NONE)	4.34
MEDIAN (EXCLUDING NONE)	15

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)

QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU REFER TO A MEDICAL ONCOLOGIST?

\* REFER TO A MEDICAL ONCOLOGIST \*

	TOTAL
BASE	20
TOTAL	357
SIGMA	20

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)  
QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU START ON TAMOXIFEN?

\* START ON TAMOXIFEN \*

	TOTAL
BASE	20
NONE	9
	45.00
2	1
	5.00
4	1
	5.00
5	2
	10.00
6	1
	5.00
20	3
	15.00
30	1
	5.00
40	1
	5.00
60	1
	5.00
MEAN (INCLUDING NONE)	10.60
STANDARD DEVIATION (INCLUDING NONE)	16.48
STANDARD ERROR (INCLUDING NONE)	3.68
MEDIAN (INCLUDING NONE)	3
MEAN (EXCLUDING NONE)	19.27
STANDARD DEVIATION (EXCLUDING NONE)	18.22
STANDARD ERROR (EXCLUDING NONE)	5.49
MEDIAN (EXCLUDING NONE)	20
TOTAL	212
SIGMA	20

(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)  
QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU TREAT WITH MASTECTOMY?

\* SUMMARY OF MEANS (INCLUDING NONE) \*

	TOTAL
BASE	20
TREAT WITH MASTECTOMY	4.35
TREAT WITH LUMPECTOMY AND RADIATION THERAPY	12.55
TREAT WITH LUMPECTOMY AND NO RADIATION THERAPY	2.80
REFER TO A MEDICAL ONCOLOGIST	17.85
START ON TAMOXIFEN	10.60



(ROTATION C AND IF "HAVE WOMEN WITH DCIS LAST YEAR" IN QUESTION 8)  
QUESTION C9. ABOUT HOW MANY OF THESE WOMEN DID YOU TREAT WITH MASTECTOMY?

\* SUMMARY OF MEANS (EXCLUDING NONE) \*

	TOTAL
BASE	20
TREAT WITH MASTECTOMY	5.44
TREAT WITH LUMPECTOMY AND RADIATION THERAPY	15.69
TREAT WITH LUMPECTOMY AND NO RADIATION THERAPY	5.60
REFER TO A MEDICAL ONCOLOGIST	21.00
START ON TAMOXIFEN	19.27

(ROTATION C)

QUESTION C10. WHAT TYPE OF RESEARCH DATA WOULD YOU REQUIRE TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN A POST-MENOPAUSAL PATIENT WITH DCIS WOMEN?

\* WOULD USE IT NOW BASED ON ATAC DATA \*

	TOTAL
BASE	20
YES	11 55.00
NO	8 40.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)

QUESTION C10. WHAT TYPE OF RESEARCH DATA WOULD YOU REQUIRE TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN A POST-MENOPAUSAL PATIENT WITH DCIS WOMEN?

\* WOULD USE IT IF ATAC TRIAL CONTINUED TO SHOW SIMILAR RESULTS WITH LONGER FOLLOW-UP \*

	TOTAL
BASE	20
YES	17 85.00
NO	2 10.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)

QUESTION C10. WHAT TYPE OF RESEARCH DATA WOULD YOU REQUIRE TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN A POST-MENOPAUSAL PATIENT WITH DCIS WOMEN?

\* WOULD USE IT IF A PRIMARY PREVENTION TRIAL DEMONSTRATED SAFETY AND EFFICACY IN HIGH-RISK WOMEN \*

	TOTAL
BASE	20
YES	16 80.00
NO	3 15.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)

QUESTION C10. WHAT TYPE OF RESEARCH DATA WOULD YOU REQUIRE TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN A POST-MENOPAUSAL PATIENT WITH DCIS WOMEN?

\* WOULD NOT USE IT \*

	TOTAL
BASE	20
YES	2 10.00
NO	17 85.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)

QUESTION C10. IS THERE SOMETHING ELSE I HAVE NOT DESCRIBED?

	TOTAL
BASE	20
YES	1 5.00
NO	18 90.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C AND IF "SOMETHING ELSE" IN QUESTION C10)  
QUESTION C10. OTHERS MENTIONED

	TOTAL
BASE	1
WOULD USE IT IF ONCOLOGISTS STARTED USING ANASTROZOLE IN THAT SETTING INSTEAD OF TAMOXIFEN	1 100.00
SIGMA	1

(ROTATION C)  
QUESTION C10. WHAT TYPE OF RESEARCH DATA WOULD YOU REQUIRE TO USE ANASTROZOLE OR ANOTHER AROMATASE INHIBITOR IN A POST-MENOPAUSAL PATIENT WITH DCIS WOMEN?

	TOTAL
BASE	20
WOULD USE IT NOW BASED ON ATAC DATA	11 55.00
WOULD USE IT IF ATAC TRIAL CONTINUED TO SHOW SIMILAR RESULTS WITH LONGER FOLLOW-UP	17 85.00
WOULD USE IT IF A PRIMARY PREVENTION TRIAL DEMONSTRATED SAFETY AND EFFICACY IN HIGH-RISK WOMEN	16 80.00
WOULD NOT USE IT	2 10.00
WOULD USE IT IF ONCOLOGISTS STARTED USING ANASTROZOLE IN THAT SETTING INSTEAD OF TAMOXIFEN	1 5.00



(ROTATION C)

QUESTION C11. WHICH OF THE FOLLOWING DESCRIBE WHAT YOU BELIEVE THE RESULTS WOULD BE OF A RANDOMIZED CLINICAL TRIAL COMPARING TAMOXIFEN TO ANASTROZOLE IN DCIS, IN TERMS OF TOXICITY?

	TOTAL
BASE	20
LESS TOXICITY WITH ANASTROZOLE	11 55.00
NO SIGNIFICANT DIFFERENCE	8 40.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION C)  
QUESTION C11A. AND, IN TERMS OF EFFICACY?

	TOTAL
BASE	20
GREATER BENEFITS WITH ANASTROZOLE	12 60.00
NO SIGNIFICANT DIFFERENCE	6 30.00
DON'T KNOW	2 10.00
SIGMA	20

(ROTATION D)

QUESTION D1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH INVASIVE BREAST CANCER?

	TOTAL
BASE	20
3	1 5.00
8	3 15.00
10	5 25.00
12	2 10.00
20	2 10.00
30	2 10.00
50	1 5.00
60	1 5.00
70	1 5.00
100	2 10.00
MEAN (INCLUDING NONE)	29.05
STANDARD DEVIATION (INCLUDING NONE)	30.53
STANDARD ERROR (INCLUDING NONE)	6.83
MEDIAN (INCLUDING NONE)	12
MEAN (EXCLUDING NONE)	29.05
STANDARD DEVIATION (EXCLUDING NONE)	30.53
STANDARD ERROR (EXCLUDING NONE)	6.83
MEDIAN (EXCLUDING NONE)	12
TOTAL	581
SIGMA	20

(ROTATION D)  
 QUESTION D2. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH NONINVASIVE BREAST CANCER?

	TOTAL
BASE	20
NONE	1 5.00
3	1 5.00
4	2 10.00
5	1 5.00
6	3 15.00
10	2 10.00
12	1 5.00
15	1 5.00
20	1 5.00
25	2 10.00
40	2 10.00
50	1 5.00
100	1 5.00
115	1 5.00
MEAN (INCLUDING NONE)	24.80
STANDARD DEVIATION (INCLUDING NONE)	31.64
STANDARD ERROR (INCLUDING NONE)	7.07
MEDIAN (INCLUDING NONE)	11
MEAN (EXCLUDING NONE)	26.11
STANDARD DEVIATION (EXCLUDING NONE)	31.95
STANDARD ERROR (EXCLUDING NONE)	7.33
MEDIAN (EXCLUDING NONE)	12
TOTAL	496
SIGMA	20

(ROTATION D)  
QUESTION D3. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* RE-EXCISION \*

	TOTAL
BASE	20
YES	7 35.00
NO	12 60.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)  
QUESTION D3. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* MASTECTOMY \*

	TOTAL
BASE	20
YES	14 70.00
NO	4 20.00
DON'T KNOW	2 10.00
SIGMA	20

(ROTATION D)  
QUESTION D3. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* CONTINUE TAMOXIFEN \*

	TOTAL
BASE	20
YES	10 50.00
NO	10 50.00
SIGMA	20

(ROTATION D)  
QUESTION D3. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR AND OVARIAN ABLATION \*

	TOTAL
BASE	20
YES	1 5.00
NO	19 95.00
SIGMA	20



(ROTATION D)  
QUESTION D3. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR \*

	TOTAL
BASE	20
YES	3 15.00
NO	17 85.00
SIGMA	20

(ROTATION D)  
QUESTION D3. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

	TOTAL
BASE	20
RE-EXCISION	7 35.00
MASTECTOMY	14 70.00
CONTINUE TAMOXIFEN	10 50.00
DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR AND OVARIAN ABLATION	1 5.00
DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR	3 15.00

(ROTATION D)

QUESTION D4. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 65 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* RE-EXCISION \*

	TOTAL
BASE	20
YES	8 40.00
NO	11 55.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)  
QUESTION D4. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 65 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* MASTECTOMY \*

	TOTAL
BASE	20
YES	14 70.00
NO	5 25.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D4. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 65 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* CONTINUE TAMOXIFEN \*

	TOTAL
BASE	20
YES	9 45.00
NO	11 55.00
SIGMA	20

(ROTATION D)  
QUESTION D4. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 65 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR AND OVARIAN ABLATION \*

	TOTAL
BASE	20
NO	20
	100.00
SIGMA	20

(ROTATION D)  
QUESTION D4. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 65 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR \*

	TOTAL
BASE	20
YES	2 10.00
NO	18 90.00
SIGMA	20

(ROTATION D)  
QUESTION D4. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 65 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

	TOTAL
BASE	20
RE-EXCISION	8 40.00
MASTECTOMY	14 70.00
CONTINUE TAMOXIFEN	9 45.00
DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR	2 10.00



(ROTATION D)  
QUESTION D5. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 78 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* RE-EXCISION \*

	TOTAL
BASE	20
YES	10 50.00
NO	9 45.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)  
QUESTION D5. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 78 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* MASTECTOMY \*

	TOTAL
BASE	20
YES	7 35.00
NO	12 60.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)  
QUESTION D5. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 78 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* CONTINUE TAMOXIFEN \*

	TOTAL
BASE	20
YES	7 35.00
NO	13 65.00
SIGMA	20

(ROTATION D)  
QUESTION D5. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 78 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR AND OVARIAN ABLATION \*

	TOTAL
BASE	20
NO	20
	100.00
SIGMA	20

(ROTATION D)  
QUESTION D5. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 78 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR \*

	TOTAL
BASE	20
YES	6 30.00
NO	14 70.00
SIGMA	20

(ROTATION D)  
QUESTION D5. IF YOU WERE PRESENTED WITH A WOMAN WHO WAS 78 YEARS OLD WITH THESE SAME CHARACTERISTICS WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

	TOTAL
BASE	20
RE-EXCISION	10 50.00
MASTECTOMY	7 35.00
CONTINUE TAMOXIFEN	7 35.00
DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR	6 30.00

(ROTATION D)

QUESTION D6. PLEASE THINK ABOUT THE 43 YEAR OLD WOMAN WHOM IS DIAGNOSED BY MAMMOGRAM WITH AN UPPER OUTER QUADRANT LESION THAT IS EXCISED AND PROVEN TO BE A 0.8 CM NONCOMEDO DCIS. THE MARGINS ARE CLEAR TO 1 CM. SHE IS TREATED WITH SURGERY. THREE YEARS LATER, SHE PRESENTS WITH A NODULE IN THE SUTURE LINE, WHICH IS EXCISED AND FOUND TO BE RECURRENT DCIS.

WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* RE-EXCISION \*

	TOTAL
BASE	20
YES	10 50.00
NO	9 45.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D6. PLEASE THINK ABOUT THE 43 YEAR OLD WOMAN WHOM IS DIAGNOSED BY MAMMOGRAM WITH AN UPPER OUTER QUADRANT LESION THAT IS EXCISED AND PROVEN TO BE A 0.8 CM NONCOMEDO DCIS. THE MARGINS ARE CLEAR TO 1 CM. SHE IS TREATED WITH SURGERY. THREE YEARS LATER, SHE PRESENTS WITH A NODULE IN THE SUTURE LINE, WHICH IS EXCISED AND FOUND TO BE RECURRENT DCIS. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* MASTECTOMY \*

	TOTAL
BASE	20
YES	12 60.00
NO	6 30.00
DON'T KNOW	2 10.00
SIGMA	20



(ROTATION D)

QUESTION D6. PLEASE THINK ABOUT THE 43 YEAR OLD WOMAN WHOM IS DIAGNOSED BY MAMMOGRAM WITH AN UPPER OUTER QUADRANT LESION THAT IS EXCISED AND PROVEN TO BE A 0.8 CM NONCOMEDO DCIS. THE MARGINS ARE CLEAR TO 1 CM. SHE IS TREATED WITH SURGERY. THREE YEARS LATER, SHE PRESENTS WITH A NODULE IN THE SUTURE LINE, WHICH IS EXCISED AND FOUND TO BE RECURRENT DCIS. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* CONTINUE TAMOXIFEN \*

	TOTAL
BASE	20
YES	11 55.00
NO	8 40.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D6. PLEASE THINK ABOUT THE 43 YEAR OLD WOMAN WHOM IS DIAGNOSED BY MAMMOGRAM WITH AN UPPER OUTER QUADRANT LESION THAT IS EXCISED AND PROVEN TO BE A 0.8 CM NONCOMEDO DCIS. THE MARGINS ARE CLEAR TO 1 CM. SHE IS TREATED WITH SURGERY. THREE YEARS LATER, SHE PRESENTS WITH A NODULE IN THE SUTURE LINE, WHICH IS EXCISED AND FOUND TO BE RECURRENT DCIS. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR AND OVARIAN ABLATION \*

	TOTAL
BASE	20
YES	3 15.00
NO	15 75.00
DON'T KNOW	2 10.00
SIGMA	20

(ROTATION D)

QUESTION D6. PLEASE THINK ABOUT THE 43 YEAR OLD WOMAN WHOM IS DIAGNOSED BY MAMMOGRAM WITH AN UPPER OUTER QUADRANT LESION THAT IS EXCISED AND PROVEN TO BE A 0.8 CM NONCOMEDO DCIS. THE MARGINS ARE CLEAR TO 1 CM. SHE IS TREATED WITH SURGERY. THREE YEARS LATER, SHE PRESENTS WITH A NODULE IN THE SUTURE LINE, WHICH IS EXCISED AND FOUND TO BE RECURRENT DCIS. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

\* DISCONTINUE TAMOXIFEN START AROMATASE INHIBITOR \*

	TOTAL
BASE	20
YES	1 5.00
NO	18 90.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D6. PLEASE THINK ABOUT THE 43 YEAR OLD WOMAN WHOM IS DIAGNOSED BY MAMMOGRAM WITH AN UPPER OUTER QUADRANT LESION THAT IS EXCISED AND PROVEN TO BE A 0.8 CM NONCOMEDO DCIS. THE MARGINS ARE CLEAR TO 1 CM. SHE IS TREATED WITH SURGERY. THREE YEARS LATER, SHE PRESENTS WITH A NODULE IN THE SUTURE LINE, WHICH IS EXCISED AND FOUND TO BE RECURRENT DCIS. WHICH OF THE FOLLOWING THERAPIES WOULD YOU BE LIKELY TO RECOMMEND?

	TOTAL
BASE	20
RE-EXCISION	10
	50.00
MASTECTOMY	12
	60.00
CONTINUE TAMOXIFEN	11
	55.00
DISCONTINUE TAMOXIFEN START	3
AROMATASE INHIBITOR AND	15.00
OVARIAN ABLATION	
DISCONTINUE TAMOXIFEN START	1
AROMATASE INHIBITOR	5.00

(ROTATION D)  
QUESTION D7. PLEASE ASSUME THAT YOU ARE PRESENTED WITH A 43 YEAR OLD WOMAN WHOM HAS A 2 CM BREAST MASS WHICH ON CORE  
BIOPSY PROVES TO BE POORLY DIFFERENTIATING INFILTRATING DUCTAL CARCINOMA, ER-NEGATIVE. THE PATIENT WISHES TO  
HAVE MASTECTOMY AND RECONSTRUCTION. WHICH OF THE FOLLOWING THERAPIES WOULD YOU GENERALLY RECOMMEND?

\* IMPLANTS \*

	TOTAL
BASE	20
YES	5 25.00
NO	14 70.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D7. PLEASE ASSUME THAT YOU ARE PRESENTED WITH A 43 YEAR OLD WOMAN WHOM HAS A 2 CM BREAST MASS WHICH ON CORE BIOPSY PROVES TO BE POORLY DIFFERENTIATING INFILTRATING DUCTAL CARCINOMA, ER-NEGATIVE. THE PATIENT WISHES TO HAVE MASTECTOMY AND RECONSTRUCTION. WHICH OF THE FOLLOWING THERAPIES WOULD YOU GENERALLY RECOMMEND?

\* LATISSIMUS DORSI \*

	TOTAL
BASE	20
YES	5 25.00
NO	15 75.00
SIGMA	20

(ROTATION D)

QUESTION D7. PLEASE ASSUME THAT YOU ARE PRESENTED WITH A 43 YEAR OLD WOMAN WHOM HAS A 2 CM BREAST MASS WHICH ON CORE BIOPSY PROVES TO BE POORLY DIFFERENTIATING INFILTRATING DUCTAL CARCINOMA, ER-NEGATIVE. THE PATIENT WISHES TO HAVE MASTECTOMY AND RECONSTRUCTION. WHICH OF THE FOLLOWING THERAPIES WOULD YOU GENERALLY RECOMMEND?

\* TRAM FLAP \*

	TOTAL
BASE	20
YES	11 55.00
NO	8 40.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D7. IS THERE SOMETHING ELSE I HAVE NOT DESCRIBED?

	TOTAL
BASE	20
YES	6 30.00
NO	14 70.00
SIGMA	20



(ROTATION D AND IF "SOMETHING ELSE" IN QUESTION D7)  
QUESTION D7. OTHER MENTIONS

	TOTAL
BASE	6
REFER TO/ CONSULT WITH PLASTIC SURGEON	5 83.33
REFER OUT TO ANOTHER CENTER	1 16.67
SIGMA	6

(ROTATION D)

QUESTION D7. PLEASE ASSUME A THAT YOU ARE PRESENTED WITH A 43 YEAR OLD WOMAN WHOM HAS A 2 CM BREAST MASS WHICH ON CORE BIOPSY PROVES TO BE POORLY DIFFERENTIATING INFILTRATING DUCTAL CARCINOMA, ER-NEGATIVE. THE PATIENT WISHES TO HAVE MASTECTOMY AND RECONSTRUCTION. WHICH OF THE FOLLOWING THERAPIES WOULD YOU GENERALLY RECOMMEND?

	TOTAL
BASE	20
IMPLANTS	5 25.00
LATISSIMUS DORSI	5 25.00
TRAM FLAP	11 55.00
REFER TO/ CONSULT WITH PLASTIC SURGEON	5 25.00
REFER OUT TO ANOTHER CENTER	1 5.00

(ROTATION D)

QUESTION D8. WHICH OF THE FOLLOWING BEST DESCRIBES THE TYPE OF TIMING YOU WOULD GENERALLY RECOMMEND IF YOU SUPPORT A PATIENT'S WISHES?

	TOTAL
BASE	20
IMMEDIATE	13 65.00
3-6 MONTHS	1 5.00
AFTER 6 MONTHS	5 25.00
2 YEARS	1 5.00
SIGMA	20

(ROTATION D)  
QUESTION D9. NOW DOCTOR, ASSUME THAT THIS SAME PATIENT HAD A PRIOR HYSTERECTOMY WITH A HORIZONTAL INCISION.  
WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

\* IMPLANTS \*

	TOTAL
BASE	20
YES	9 45.00
NO	11 55.00
SIGMA	20

(ROTATION D)  
QUESTION D9. NOW DOCTOR, ASSUME THAT THIS SAME PATIENT HAD A PRIOR HYSTERECTOMY WITH A HORIZONTAL INCISION.  
WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

\* LATISSIMUS DORSI \*

	TOTAL
BASE	20
YES	8 40.00
NO	12 60.00
SIGMA	20

(ROTATION D)  
QUESTION D9. NOW DOCTOR, ASSUME THAT THIS SAME PATIENT HAD A PRIOR HYSTERECTOMY WITH A HORIZONTAL INCISION.  
WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

\* TRAM FLAP \*

	TOTAL
BASE	20
YES	3 15.00
NO	17 85.00
SIGMA	20

(ROTATION D)

QUESTION D9. IS THERE SOMETHING ELSE I HAVEN'T MENTIONED?

	TOTAL
BASE	20
YES	3 15.00
NO	17 85.00
SIGMA	20

REED, HALDY, MCINTOSH & ASSOCIATES  
MEDIA, PENNSYLVANIA  
Page 96  
Table 92

MIAMI MEETING SURVEY - SURGEONS  
JANUARY, 2002 - STUDY 0329

(ROTATION D AND IF "SOMETHING ELSE" IN QUESTION D9)  
QUESTION D9. OTHER MENTIONS

	TOTAL
BASE	3
REFER TO/ CONSULT WITH PLASTIC SURGEON	3 100.00
SIGMA	3



(ROTATION D)  
QUESTION D9. NOW DOCTOR, ASSUME THAT THIS SAME PATIENT HAD A PRIOR HYSTERECTOMY WITH A HORIZONTAL INCISION.  
WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

	TOTAL
BASE	20
IMPLANTS	9 45.00
LATISSIMUS DORSI	8 40.00
TRAM FLAP	3 15.00
REFER TO/ CONSULT WITH PLASTIC SURGEON	3 15.00

(ROTATION D)

QUESTION D10. WHICH OF THE FOLLOWING BEST DESCRIBES THE TYPE OF TIMING YOU WOULD GENERALLY RECOMMEND IF YOU SUPPORT A PATIENT'S WISHES?

	TOTAL
BASE	20
IMMEDIATE	12 60.00
3-6 MONTHS	2 10.00
AFTER 6 MONTHS	5 25.00
2 YEARS	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D11. PLEASE ASSUME THE PATIENT WAS 62 YEARS OLD. WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

\* IMPLANTS \*

	TOTAL
BASE	20
YES	12 60.00
NO	8 40.00
SIGMA	20

(ROTATION D)

QUESTION D11. PLEASE ASSUME THE PATIENT WAS 62 YEARS OLD. WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

\* LATISSIMUS DORSI \*

	TOTAL
BASE	20
YES	3 15.00
NO	17 85.00
SIGMA	20

(ROTATION D)

QUESTION D11. PLEASE ASSUME THE PATIENT WAS 62 YEARS OLD. WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

\* TRAM FLAP \*

	TOTAL
BASE	20
YES	5 25.00
NO	15 75.00
SIGMA	20

(ROTATION D)

QUESTION D11. IS THERE SOMETHING ELSE I HAVE NOT DESCRIBED?

	TOTAL
BASE	20
YES	5 25.00
NO	15 75.00
SIGMA	20

REED, HALDY, MCINTOSH & ASSOCIATES  
MEDIA, PENNSYLVANIA  
Page 103  
Table 99

MIAMI MEETING SURVEY - SURGEONS  
JANUARY, 2002 - STUDY 0329

(ROTATION D AND "SOMETHING ELSE" IN QUESTION D11)  
QUESTION D11. OTHER MENTIONS

	TOTAL
BASE	5
REFER TO/ CONSULT WITH PLASTIC SURGEON	5 100.00
SIGMA	5

(ROTATION D)

QUESTION D11. PLEASE ASSUME THE PATIENT WAS 62 YEARS OLD. WHICH OF THE FOLLOWING WOULD YOU GENERALLY RECOMMEND?

	TOTAL
BASE	20
IMPLANTS	12
	60.00
LATISSIMUS DORSI	3
	15.00
TRAM FLAP	5
	25.00
REFER TO/ CONSULT WITH PLASTIC SURGEON	5
	25.00



(ROTATION D)

QUESTION D12. WHICH OF THE FOLLOWING BEST DESCRIBES THE TYPE OF TIMING YOU WOULD GENERALLY RECOMMEND IF YOU SUPPORT  
A PATIENT'S WISHES?

	TOTAL
BASE	20
IMMEDIATE	10 50.00
3-6 MONTHS	5 25.00
AFTER 6 MONTHS	4 20.00
2 YEARS	1 5.00
SIGMA	20

(ROTATION D)

QUESTION D13. PLEASE TELL ME WHETHER OR NOT YOU WOULD RECOMMEND POST MASTECTOMY RADIATION THERAPY?

ROTATION D										
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10
AGE	43	43	43	43	65	65	65	65	78	78
TUMOR SIZE (CM)	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
NODES	NEG	1+	3+	5+	NEG	1+	3+	5+	3+	5+
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
YES	5 25.00	11 55.00E	15 75.00AE	16 80.00AE	4 20.00	9 45.00	13 65.00AE	16 80.00AE	13 65.00AE	15 75.00AE
NO	14 70.00CD GHIJ	8 40.00D	4 20.00	2 10.00	15 75.00BC DGHIJ	10 50.00DH	6 30.00	3 15.00	6 30.00	4 20.00
DON'T KNOW	1 5.00	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00
SIGMA	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION E)  
 QUESTION E1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH INVASIVE BREAST CANCER?

	TOTAL
BASE	20
5	2 10.00
15	2 10.00
20	4 20.00
25	3 15.00
35	1 5.00
50	2 10.00
60	2 10.00
70	1 5.00
80	1 5.00
150	2 10.00
MEAN (INCLUDING NONE)	45.00
STANDARD DEVIATION (INCLUDING NONE)	41.80
STANDARD ERROR (INCLUDING NONE)	9.35
MEDIAN (INCLUDING NONE)	25
MEAN (EXCLUDING NONE)	45.00
STANDARD DEVIATION (EXCLUDING NONE)	41.80
STANDARD ERROR (EXCLUDING NONE)	9.35
MEDIAN (EXCLUDING NONE)	25
TOTAL	900
SIGMA	20

(ROTATION E)

QUESTION E2. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH NONINVASIVE BREAST CANCER?

	TOTAL
BASE	20
NONE	1 5.00
2	2 10.00
5	1 5.00
10	3 15.00
20	2 10.00
25	1 5.00
30	3 15.00
35	1 5.00
40	2 10.00
100	1 5.00
200	2 10.00
250	1 5.00
MEAN (INCLUDING NONE)	52.95
STANDARD DEVIATION (INCLUDING NONE)	74.45
STANDARD ERROR (INCLUDING NONE)	16.65
MEDIAN (INCLUDING NONE)	28
MEAN (EXCLUDING NONE)	55.74
STANDARD DEVIATION (EXCLUDING NONE)	75.41
STANDARD ERROR (EXCLUDING NONE)	17.30
MEDIAN (EXCLUDING NONE)	30
TOTAL	1059
SIGMA	20

(ROTATION E)  
QUESTION E3. WHAT ARE THE THREE MOST COMMON COMPLIMENTARY TREATMENTS YOUR BREAST CANCER PATIENTS MOST COMMONLY USE IN  
ADDITION TO SURGICAL AND PHARMACEUTICAL TREATMENTS YOU RECOMMEND?

	TOTAL
BASE	20
DIET	8 40.00
VITMAINS/MINERAL SUPPLEMENTS	4 20.00
HERBS	3 15.00
EXERCISE	2 10.00
OTHER	3 15.00
NONE	6 30.00
DON'T KNOW	3 15.00
SIGMA	29

(ROTATION E AND "OTHER MENTIONED" IN QUESTION E3)  
QUESTION E3. WHAT IS THE FIRST OTHER MENTIONED?

	TOTAL
BASE	3
SOY	1 33.33
SUPPORT GROUPS	1 33.33
REFER TO AMERICAN CANCER SOCIETY REPS	1 33.33
SIGMA	3

(ROTATION E AND "DIET" USED IN QUESTION E3)  
QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY USE DIET?

\* DIET \*

	TOTAL
BASE	8
1 - 10 %	1 12.50
11 - 20 %	2 25.00
21 - 30 %	2 25.00
41 - 50 %	1 12.50
81 - 90 %	1 12.50
100 %	1 12.50
MEAN (INCLUDING NONE)	42.50
STANDARD DEVIATION (INCLUDING NONE)	34.64
STANDARD ERROR (INCLUDING NONE)	12.25
MEDIAN (INCLUDING NONE)	28
SIGMA	8

(ROTATION E AND "EXERCISE" USED IN QUESTION E3)

QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY USE EXERCISE?

\* EXERCISE \*

	TOTAL
BASE	2
21 - 30 %	1 50.00
71 - 80 %	1 50.00
MEAN (INCLUDING NONE)	52.50
STANDARD DEVIATION (INCLUDING NONE)	31.82
STANDARD ERROR (INCLUDING NONE)	22.50
MEDIAN (INCLUDING NONE)	53
SIGMA	2



(ROTATION E AND "HERBS" USED IN QUESTION E3)

QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY USE HERBS?

\* HERBS \*

	TOTAL
BASE	3
11 - 20 %	2 66.67
21 - 30 %	1 33.33
MEAN (INCLUDING NONE)	20.00
STANDARD DEVIATION (INCLUDING NONE)	5.00
STANDARD ERROR (INCLUDING NONE)	2.89
MEDIAN (INCLUDING NONE)	20
SIGMA	3

(ROTATION E AND "VITAMINS/MINERAL SUPPLEMENTS" USED IN QUESTION E3)

QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY USE VITAMINS/ MINERAL SUPPLEMENTS?

\* VITAMINS/MINERAL SUPPLEMENTS \*

	TOTAL
BASE	4
1 - 10 %	1 25.00
41 - 50 %	2 50.00
71 - 80 %	1 25.00
MEAN (INCLUDING NONE)	46.25
STANDARD DEVIATION (INCLUDING NONE)	26.89
STANDARD ERROR (INCLUDING NONE)	13.44
MEDIAN (INCLUDING NONE)	50
SIGMA	4

(ROTATION E AND "SOY" MENTIONED IN QUESTION E3)

QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY USE SOY?

\* SOY \*

	TOTAL
BASE	1
41 - 50 %	1 100.00
MEAN (INCLUDING NONE)	50.00
MEDIAN (INCLUDING NONE)	50
SIGMA	1

(ROTATION E AND "SUPPORT GROUPS" MENTIONED IN QUESTION E3)

QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY USE SUPPORT GROUPS?

\* SUPPORT GROUPS \*

	TOTAL
BASE	1
21 - 30 %	1 100.00
MEAN (INCLUDING NONE)	25.00
MEDIAN (INCLUDING NONE)	25
SIGMA	1

(ROTATION E AND "REFER TO AMERICAN CANCER SOCIETY" MENTIONED IN QUESTION E3)

QUESTION E3A. IN YOUR BEST ESTIMATE, WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ACTIVELY REFER TO AMERICAN CANCER SOCIETY REPS?

\* REFER TO AMERICAN CANCER SOCIETY REPS\*

	TOTAL
BASE	1
71 - 80 %	1 100.00
MEAN (INCLUDING NONE)	75.00
MEDIAN (INCLUDING NONE)	75
SIGMA	1

(ROTATION E)  
QUESTION E3A. MOST COMMON COMPLIMENTARY TREATMENTS BREAST CANCER PATIENTS MOST COMMONLY USE IN ADDITION TO SURGICAL AND  
PHARMACEUTICAL TREATMENTS YOU RECOMMEND

\* SUMMARY OF MEANS \*

	TOTAL
BASE	20
DIET	42.50
EXERCISE	52.50
HERBS	20.00
VITAMINS/MINERAL SUPPLEMENTS	46.25
SOY	50.00
SUPPORT GROUPS	25.00
REFER TO AMERICAN CANCER SOCIETY REPS	75.00

(ROTATION E)

QUESTION E4. ABOUT WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS DO YOU BELIEVE ARE ACCESSING HEALTH INFORMATION RELATED TO THEIR TREATMENT FROM THE INTERNET?

	TOTAL
BASE	20
NONE	1 5.00
1 - 10 %	3 15.00
11 - 20 %	1 5.00
21 - 30 %	3 15.00
41 - 50 %	6 30.00
61 - 70 %	1 5.00
71 - 80 %	1 5.00
81 - 90 %	4 20.00
MEAN (INCLUDING NONE)	46.00
STANDARD DEVIATION (INCLUDING NONE)	29.58
STANDARD ERROR (INCLUDING NONE)	6.62
MEDIAN (INCLUDING NONE)	50
MEAN (EXCLUDING NONE)	48.42
STANDARD DEVIATION (EXCLUDING NONE)	28.29
STANDARD ERROR (EXCLUDING NONE)	6.49
MEDIAN (EXCLUDING NONE)	50
SIGMA	20

(ROTATION E)  
QUESTION E5. ABOUT WHAT PERCENTAGE OF YOUR BREAST CANCER PATIENTS ARE BRINGING TO YOUR ATTENTION HEALTH INFORMATION RELATED TO THEIR TREATMENT FROM THE INTERNET?

	TOTAL
BASE	20
NONE	2 10.00
1 - 10 %	6 30.00
11 - 20 %	1 5.00
21 - 30 %	4 20.00
31 - 40 %	1 5.00
41 - 50 %	4 20.00
71 - 80 %	1 5.00
100 %	1 5.00
MEAN (INCLUDING NONE)	28.90
STANDARD DEVIATION (INCLUDING NONE)	26.95
STANDARD ERROR (INCLUDING NONE)	6.03
MEDIAN (INCLUDING NONE)	25
MEAN (EXCLUDING NONE)	32.11
STANDARD DEVIATION (EXCLUDING NONE)	26.50
STANDARD ERROR (EXCLUDING NONE)	6.25
MEDIAN (EXCLUDING NONE)	28
SIGMA	20



(ROTATION E)

QUESTION E6. DO YOU BELIEVE THAT SCREENING MAMMOGRAPHY SIGNIFICANTLY LOWERS THE CHANCE OF DYING OF BREAST CANCER?

	TOTAL
BASE	20
YES	18 90.00
NO	2 10.00
SIGMA	20

(ROTATION E)  
QUESTION E7. DO YOU BELIEVE THAT SCREENING MAMMOGRAPHY SIGNIFICANTLY LOWERS THE CHANCE OF REQUIRING A MASTECTOMY  
TO TREAT BREAST CANCER?

	TOTAL
BASE	20
YES	19 95.00
NO	1 5.00
SIGMA	20

(ROTATION E)

QUESTION E9. WHICH OF THE FOLLOWING BIOPSY TECHNIQUES DO YOU GENERALLY USE FOR PALPABLE BREAST MASSES THAT YOU SUSPECT TO BE CANCERS?

	TOTAL
BASE	20
14 GAUGE CORE NEEDLE BIOPSY	15 75.00
FINE NEEDLE ASPIRATION	12 60.00
EXCISION/ OPEN SURGICAL BIOPSY	8 40.00
11 GAUGE CORE NEEDLE BIOPSY	7 35.00
16 GAUGE CORE NEEDLE BIOPSY	2 10.00
14 GAUGE CORE MAMMETONE	1 5.00
18 GAUGE CORE NEEDLE BIOPSY	1 5.00
ULTRASOUND GUIDED 14 GAUGE NEEDLE	1 5.00
SIGMA	47

(ROTATION E)

QUESTION E10. WHICH OF THE FOLLOWING BIOPSY TECHNIQUES DO YOU GENERALLY USE FOR NONPALPABLE MICROCALCIFICATIONS WHICH ARE NEGATIVE ON ULTRASOUND?

	TOTAL
BASE	20
SINGLE WIRE LOCALIZATION AND BIOPSY	18 90.00
PERCUTANEOUS STEREOTACTIC CORE NEEDLE BIOPSY	16 80.00
BRACKETED WIRE LOCALIZATION AND BIOPSY	6 30.00
PERCUTANEOUS STEREOTACTIC FINE NEEDLE BIOPSY	2 10.00
DYE IN ADDITION TO WIRE	1 5.00
HOOK WIRE LOCALIZATION (UNSPECIFIED)	1 5.00
SIGMA	44

(ROTATION E)

QUESTION E11. WHICH OF THE FOLLOWING BIOPSY TECHNIQUES DO YOU GENERALLY USE FOR NONPALPABLE MASS ON MAMMOGRAM WHICH IS IDENTIFIED TO BE A SOLID LESION ULTRASOUND?

	TOTAL
BASE	20
WIRE LOCALIZATION AND BIOPSY	17 85.00
ULTRASONIC PERCUTANEOUS CORE NEEDLE BIOPSY	14 70.00
STEREOTACTIC PERCUTANEOUS CORE NEEDLE BIOPSY	14 70.00
ULTRASONIC PERCUTANEOUS FINE NEEDLE ASPIRATION	7 35.00
STEREOTACTIC PERCUTANEOUS FINE NEEDLE ASPIRATION	4 20.00
SIGMA	56

(ROTATION E)  
QUESTION E12. ABOUT HOW MANY SENTINEL NODE BIOPSIES HAVE YOU PERFORMED IN THE LAST YEAR?

	TOTAL
BASE	20
NONE	7
	35.00
2	1
	5.00
5	1
	5.00
12	1
	5.00
15	3
	15.00
20	2
	10.00
22	1
	5.00
25	1
	5.00
30	2
	10.00
100	1
	5.00
MEAN (INCLUDING NONE)	15.55
STANDARD DEVIATION (INCLUDING NONE)	22.62
STANDARD ERROR (INCLUDING NONE)	5.06
MEDIAN (INCLUDING NONE)	14
MEAN (EXCLUDING NONE)	23.92
STANDARD DEVIATION (EXCLUDING NONE)	24.35
STANDARD ERROR (EXCLUDING NONE)	6.75
MEDIAN (EXCLUDING NONE)	20
TOTAL	311
SIGMA	20

(ROTATION E AND "PERFORMED AT LEAST ONE SENTINEL NODE BIOPSY" IN QUESTION E12)  
QUESTION E13. WHICH OF THE FOLLOWING TECHNIQUES DO YOU GENERALLY UTILIZE?

	TOTAL
BASE	13
BOTH	11 84.62
RADIOISOTOPE	1 7.69
DYE	1 7.69
SIGMA	13

(ROTATION E AND "PERFORMED AT LEAST ONE SENTINEL NODE BIOPSY" IN QUESTION E12)  
QUESTION E14. ABOUT WHAT PERCENTAGE OF THESE PROCEDURES HAVE BEEN POSITIVE?

	TOTAL
BASE	13
NONE	2 15.38
1 - 10 %	2 15.38
11 - 20 %	3 23.08
21 - 30 %	2 15.38
41 - 50 %	1 7.69
81 - 90 %	3 23.08
MEAN (INCLUDING NONE)	33.08
STANDARD DEVIATION (INCLUDING NONE)	34.07
STANDARD ERROR (INCLUDING NONE)	9.45
MEDIAN (INCLUDING NONE)	20
MEAN (EXCLUDING NONE)	39.09
STANDARD DEVIATION (EXCLUDING NONE)	33.68
STANDARD ERROR (EXCLUDING NONE)	10.15
MEDIAN (EXCLUDING NONE)	25
SIGMA	13



(ROTATION E)

QUESTION E15. ABOUT HOW MANY AXILLARY DISSECTIONS HAVE YOU PERFORMED IN THE PAST YEAR, WITHOUT SENTINEL BIOPSY?

	TOTAL
BASE	20
NONE	1 5.00
1	1 5.00
2	1 5.00
5	1 5.00
7	1 5.00
10	1 5.00
12	2 10.00
15	1 5.00
20	3 15.00
25	3 15.00
30	1 5.00
40	1 5.00
45	1 5.00
50	2 10.00
MEAN (INCLUDING NONE)	20.70
STANDARD DEVIATION (INCLUDING NONE)	15.77
STANDARD ERROR (INCLUDING NONE)	3.53
MEDIAN (INCLUDING NONE)	20
MEAN (EXCLUDING NONE)	21.79
STANDARD DEVIATION (EXCLUDING NONE)	15.40
STANDARD ERROR (EXCLUDING NONE)	3.53
MEDIAN (EXCLUDING NONE)	20
TOTAL	414
SIGMA	20

QUESTION 6. HOW MANY BREAST CANCER PATIENTS DO YOU PERSONALLY SEE IN YOUR OFFICE PER MONTH?

	TOTAL
BASE	100
1	5 5.00
2	11 11.00
3	14 14.00
4	11 11.00
5	9 9.00
6	1 1.00
7	1 1.00
8	2 2.00
9	1 1.00
10	9 9.00
11	1 1.00
12	2 2.00
13	1 1.00
15	6 6.00
16	1 1.00
20	9 9.00
25	1 1.00
30	2 2.00
40	4 4.00
50	2 2.00
60	1 1.00
100	1 1.00

QUESTION 6. HOW MANY BREAST CANCER PATIENTS DO YOU PERSONALLY SEE IN YOUR OFFICE PER MONTH?

	TOTAL
BASE	100
150	2 2.00
200	1 1.00
500	1 1.00
DON'T KNOW	1 1.00
MEAN (INCLUDING NONE)	21.46
STANDARD DEVIATION (INCLUDING NONE)	57.53
STANDARD ERROR (INCLUDING NONE)	5.78
MEDIAN (INCLUDING NONE)	5
MEAN (EXCLUDING NONE)	21.46
STANDARD DEVIATION (EXCLUDING NONE)	57.53
STANDARD ERROR (EXCLUDING NONE)	5.78
MEDIAN (EXCLUDING NONE)	5
TOTAL	2125
SIGMA	100

QUESTION 7. IS YOUR PRACTICE AFFILIATED WITH A UNIVERSITY HOSPITAL?

	TOTAL
BASE	100
YES	14 14.00
NO	86 86.00
SIGMA	100

	TOTAL
BASE	100
35	3 3.00
36	1 1.00
38	3 3.00
39	2 2.00
40	3 3.00
41	4 4.00
42	8 8.00
43	4 4.00
44	3 3.00
45	5 5.00
46	4 4.00
47	2 2.00
48	1 1.00
49	2 2.00
50	3 3.00
51	2 2.00
52	2 2.00
53	2 2.00
54	2 2.00
55	7 7.00
56	2 2.00
57	2 2.00

	TOTAL
BASE	100
58	2 2.00
59	3 3.00
60	4 4.00
61	1 1.00
62	3 3.00
63	2 2.00
64	1 1.00
66	4 4.00
67	4 4.00
68	1 1.00
69	1 1.00
70	2 2.00
71	1 1.00
72	1 1.00
73	1 1.00
77	1 1.00
DON'T KNOW/REFUSED	1 1.00
MEAN	52.11
STANDARD DEVIATION	10.53
STANDARD ERROR	1.06
MEDIAN	51
TOTAL	5159
SIGMA	100

	TOTAL
BASE	100
MALE	94 94.00
FEMALE	6 6.00
SIGMA	100